Does TRT Affect Longevity? What the Research Says About Testosterone and Lifespan

Does testosterone replacement therapy help you live longer, shorten your life, or make no meaningful difference? This question sits at the center of a long-running debate in endocrinology, cardiology, and men's health — and the answer depends on which studies you read and how they're interpreted.

The relationship between testosterone and mortality is not straightforward. Observational studies consistently show that men with low testosterone have higher all-cause mortality than men with normal levels. But whether normalizing testosterone through TRT closes that gap — or closes it without introducing new risks — has taken decades of research to untangle.

Low Testosterone and Higher Mortality: The Consensus Finding

Multiple large observational studies have documented that men with low circulating testosterone die earlier than men with normal levels. A meta-analysis published in the European Heart Journal pooled data from 13 studies involving over 8,000 men and found that low testosterone was associated with a hazard ratio of approximately 1.40 for all-cause mortality — meaning roughly a 40% higher risk of death over follow-up periods of 4 to 21 years.

This association held across age groups and persisted after adjusting for body mass index, smoking status, diabetes, and other confounding factors. Men with hypogonadism also showed higher cardiovascular mortality in most of the included studies.

The critical caveat: association is not causation. Low testosterone could be a marker of poor health rather than a cause of it. Men with chronic illness, obesity, diabetes, and metabolic syndrome tend to have lower testosterone levels. These same conditions independently increase mortality risk — making it difficult to say whether testosterone itself is protective or simply correlates with better overall health.

What Does TRT Do to Mortality Risk?

The question of whether treating low testosterone actually changes mortality outcomes — as opposed to confirming that men who are healthier have higher testosterone — requires different study designs. Several large studies have addressed this:

TRAVERSE Trial (2023)

The largest and most important recent study is the Testosterone Replacement Therapy for Assessment of Long-term Vascular Events and Efficacy Response (TRAVERSE) trial, published in the New England Journal of Medicine in 2023. It randomized over 5,200 men aged 45-80 with confirmed hypogonadism and pre-existing cardiovascular disease or high cardiovascular risk to receive either testosterone gel or placebo gel for an average of 2.2 years.

The primary finding: TRT was non-inferior to placebo for major adverse cardiovascular events (MACE) — a composite of heart attack, stroke, and cardiovascular death. This means TRT did not increase cardiovascular risk compared to placebo in this high-risk population. The result addressed a major concern that had persisted after smaller, earlier studies suggested possible cardiovascular harm.

TRAVERSE was not designed to test mortality directly — cardiovascular events were its focus. But the absence of increased MACE in a high-risk cohort is reassuring for the broader longevity question: if TRT were meaningfully harmful for lifespan, you'd expect to see signal in cardiovascular events in this population.

Retrospective Registry Studies Suggest Benefit

Several retrospective studies using large healthcare databases have reported lower mortality in men treated with TRT compared to untreated hypogonadal men. A 2019 study using data from over 1,200 men in a Veterans Affairs medical center found that men who received TRT had significantly lower all-cause mortality over follow-up compared to untreated men with low testosterone.

Another study published in the European Urology journal analyzed over 1,000 men who underwent coronary angiography and found that those with low testosterone who received TRT had lower all-cause mortality over 10 years compared to both untreated low-testosterone men and even some men with normal testosterone levels.

These studies are compelling but limited by their observational, retrospective design. Men who receive TRT may differ from untreated men in ways that are difficult to fully adjust for — they may be more engaged with their healthcare, have better access to care, or have fewer severe comorbidities that would contraindicate TRT.

Mechanisms Where TRT Could Affect Longevity

Plausible biological mechanisms exist in both directions:

Pathways That Could Reduce Mortality

Body composition: Testosterone increases lean muscle mass and reduces visceral fat. Visceral adiposity is an independent predictor of all-cause mortality, and TRT produces clinically meaningful reductions in fat mass — particularly visceral fat — even without exercise, according to the JAMA meta-analysis of 38 randomized trials.

Bone density: Hypogonadism increases osteoporosis and fracture risk, and fractures in older men are associated with significant excess mortality. TRT increases bone mineral density, potentially reducing fracture risk in aging men.

Metabolic function: Low testosterone is associated with insulin resistance and increased diabetes risk. TRT improves insulin sensitivity and glycemic control in hypogonadal men with type 2 diabetes, potentially reducing diabetes-related complications.

Mood and cognition: Depression and cognitive decline are associated with higher mortality in aging men. TRT has been shown to improve mood in hypogonadal men with clinical depression, though the effects are modest.

Physical function: Strength and mobility decline with low testosterone. Falls and loss of functional independence are major contributors to mortality and reduced quality of life in older men.

Pathways That Could Introduce Risk

Polycythemia: Testosterone increases hematocrit and hemoglobin, sometimes to pathological levels. Elevated hematocrit increases blood viscosity and thrombotic risk. This is the most common clinically significant side effect of TRT and requires ongoing monitoring and occasional therapeutic phlebotomy.

Cardiovascular strain: The TRAVERSE trial largely addressed major cardiovascular events, but the long-term effects of supraphysiological or even high-normal testosterone levels on cardiac structure and function remain incompletely studied. Some animal models and case reports suggest testosterone can contribute to left ventricular hypertrophy and arrhythmias, though this appears to be dose-dependent and less common at physiological replacement doses.

Sleep apnea: TRT can worsen or trigger obstructive sleep apnea in susceptible men, and untreated sleep apnea is an independent cardiovascular mortality risk factor.

What the Data Does Not Say

It is important to be clear about the limits of the evidence:

• No randomized trial has demonstrated that TRT extends lifespan. TRAVERSE tested cardiovascular safety, not mortality. The observational studies suggesting reduced mortality with TRT are subject to confounding by indication and healthy-user bias.
• "More is not better" does not apply to longevity. The relationship between testosterone and mortality often appears U-shaped, with both very low and very high levels associated with increased risk. The TRAVERSE trial used physiological replacement doses, not supraphysiological doses.
• TRT is not a longevity intervention. Treating confirmed hypogonadism and normalizing testosterone is different from using testosterone in eugonadal men to extend life. There is no evidence supporting the latter.

A Practical Framework

The most defensible conclusion from the current evidence is this: if you have confirmed hypogonadism — symptomatic low testosterone on multiple morning lab tests — TRT is unlikely to reduce your lifespan and may modestly reduce mortality risk by correcting the factors that make hypogonadism a risk marker. The TRAVERSE trial provides the strongest available evidence that TRT does not increase major cardiovascular events in a high-risk population.

What matters is doing TRT properly:

• Confirm hypogonadism with proper labs: Total testosterone on at least two separate morning draws, plus LH, FSH, SHBG, and free testosterone. See our lab monitoring guide.
• Maintain physiological levels: Target mid-normal range, not supraphysiological. Higher doses increase polycythemia risk without proven additional benefits.
• Monitor hematocrit: Check at baseline, 3-6 months after initiation, and every 6-12 months thereafter. This is the single most important safety lab on TRT.
• Monitor cardiovascular risk factors: Blood pressure, lipid panel, fasting glucose or HbA1c, and waist circumference. Address modifiable risks aggressively.
• Treat sleep apnea if present: If you develop or worsen snoring and daytime sleepiness on TRT, get a sleep study.
• Follow up with your provider: Regular clinical reassessment ensures dose adjustments and monitoring stay on track.

Bottom Line

The claim that "low testosterone kills" is overstated — low T is associated with higher mortality, but it may be a marker rather than a cause. The claim that "TRT extends life" is also unsupported — no randomized mortality trial exists. What the current evidence does support is that properly managed TRT at physiological doses in confirmed hypogonadal men is cardiovascularly safe (TRAVERSE, 2023) and may improve the metabolic, body composition, and functional factors associated with shorter lifespan.

For men considering TRT, the most important question is not "will this make me live longer?" but "will this improve my quality of life without introducing unacceptable risks?" On that question, the evidence is considerably stronger.